Image Courtesy: Getty Images
Researchers have reported encouraging results from an experimental personalized cancer vaccine, with none of nine kidney cancer patients experiencing a recurrence during a median follow-up of approximately three years and four months after surgery.
The vaccine was designed using protein fragments from each patient’s tumor to help the immune system identify and attack cancer cells. The findings suggest that personalized vaccines could become a promising approach to preventing cancer from returning, although the small study cannot establish whether the treatment was responsible for the results.
All nine participants had clear cell renal cell carcinoma, the most common type of kidney cancer in adults. Seven had stage III disease, while two had stage IV disease. Although surgery had removed their tumors and no disease was detectable when vaccination began, they remained at high risk of recurrence.
To create the vaccines, researchers analyzed tumor samples collected during surgery and identified neoantigens. These are abnormal protein fragments produced by cancer-specific genetic mutations that can help the immune system distinguish cancer cells from healthy tissue.
Every participant received a vaccine tailored to their tumor. Five also received the immunotherapy drug ipilimumab near the vaccination site, while four received the vaccine alone.
All nine patients developed immune responses against their vaccine targets. These responses persisted for years, and researchers found that vaccine-reactive T cells could recognize the patients’ own tumor cells in seven cases.
The treatment also showed a promising safety profile. The most common side effects were injection-site reactions and temporary flu-like symptoms. No participant experienced a treatment-related adverse event classified as grade 3 or higher, indicating severe toxicity.
However, researchers cautioned against interpreting the results as proof that the vaccine prevents cancer recurrence. The phase 1 trial primarily assessed safety and immune responses, rather than treatment effectiveness. Without a control group, it remains unclear whether the patients would have remained cancer-free without vaccination.
Researchers David Braun of Yale University and Toni Choueiri of Dana-Farber Cancer Institute and Harvard Medical School emphasized the need for larger studies to determine whether personalized vaccines improve patient outcomes.
A larger randomized trial, INTerpath-004, is evaluating a different personalized mRNA cancer vaccine alongside pembrolizumab, an immunotherapy drug, in patients with kidney cancer.
The early findings demonstrate that personalized vaccines can trigger lasting immune responses against kidney tumors. Whether this approach can reliably prevent cancer from returning will depend on the results of larger clinical trials.
